Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

Egalet’s extended-release, abuse-deterrent opioid succeeds in Ph3 trial

November 28, 2017 By Sarah Faulkner Leave a Comment

EgaletShares in Egalet Corp. (NSDQ:EGLT) soared this morning in pre-market activity after the company reported that its abuse-deterrent, extended-release oxycodone candidate met the primary endpoint of a Phase III pain relief trial.

The Wayne, Penn.-based company compared the efficacy and safety of its product to a placebo in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain.

The study showed a statistically significant difference in average pain intensity from baseline to week 16 between those treated with Egalet-002 and a placebo, Egalet reported.

Egalet-002 is made of the company’s Guardian polymer matrix tablet technology, which gives the pills physical and chemical properties designed to resist crushing or grinding. The pills are also harder to manipulate chemically, according to Egalet, and turn into a viscous hydrogel on contact with liquid.

“These results demonstrate Egalet-002, an abuse-deterrent, extended-release oxycodone, provided effective pain relief for patients with moderate-to-severe chronic back pain,” president & CEO Bob Radie said in prepared remarks. “Given the prevalence of chronic back pain combined with the prescription abuse epidemic, we believe development of more abuse-deterrent products like Egalet-002 is important for our communities.”

EGLT shares were trading at $1.38 apiece in pre-market activity today, up 15%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: egalet

IN CASE YOU MISSED IT

  • Senseonics partners to provide veterans with Eversense CGM
  • Tandem wins interoperable claim for insulin pump from FDA
  • Ocugen wins orphan drug status for ocular gene therapy
  • Inovio prices $65m senior notes offering
  • FDA committee backs J&J’s nasal spray for depression

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS